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Abstract
Background: To evaluate the effects of an ovulation triggering agent, human chorionic gonadotropin (hCG), versus
a gonadotropin-releasing hormone agonist (GnRHa) on early embryo development in vitro using a time-lapse
system.
Methods: Retrospective analysis of a prospectively collected database. A total of 739 embryos from 152 infertile
couples undergoing intracytoplasmic sperm injection cycles.
Interventions : Embryo culture in a time-lapse incubator (EmbryoScope, Vitrolife, Göteborg, Sweden). Main Outcome
Measures: Embryo morphokinetic parameters.
Results: In the 152 women, 252 embryos were derived from GnRHa-triggered cycles compared with 487 embryos
derived from hCG-triggered cycles. Time-lapse analysis revealed that embryos from cycles triggered by a GnRHa
cleaved faster than embryos derived from hCG-triggered cycles.
Conclusion: Triggering with a GnRHa in in vitro fertilization cycles affects embryo kinetics.
Keywords: Agonist trigger, Oocyte, Embryo quality, Time lapse, Morphokinetic
Background
Embryo quality is one of the most important factors af-
fecting the success of in vitro fertilization (IVF). Currently,
embryo quality is determined using morphological evalu-
ation methods, and in most circumstances the embryolo-
gist’s decision is the last step in choosing the embryo that
is transferred to the patient. Although morphological
evaluation has been the gold standard for many years, it is
a subjective process with inter- and intra-observer vari-
ability [1]. It is also a static evaluation method, and some
abnormalities cannot be detected over the time interval
involved in embryo evaluation. Time-lapse monitoring is a
new technology that enables dynamic, more objective
evaluation of embryos [2, 3].
The treatment protocol and duration and the type and
dosage of drugs are clinician-dependent factors that
might affect oocyte and embryo quality. Initially, IVF
treatment was performed in a natural cycle; however,
over the last 20 years many different treatment protocols
have been used [4]. Gonadotropin-releasing hormone
agonists (GnRHa) have long been used to inhibit prema-
ture luteinizing hormone (LH) release. In the last
decade, however, a GnRH antagonist protocol has be-
come preferred for pituitary desensitization worldwide,
because it is a more patient friendly approach that also
reduces the risk of ovarian hyperstimulation syndrome
(OHSS) [5]. Another advantage of antagonist cycles is
they enable the use of a GnRHa for triggering final
oocyte maturation. There are some physiological differ-
ences between human chorionic gonadotropin (hCG)
and GnRHa triggers. Unlike hCG triggering of final
oocyte maturation, GnRHa triggering is a more physio-
logical approach, eliciting a surge of gonadotropins
similar to that of the natural mid-cycle surge [6]. The
serum LH and follicle-stimulating hormone (FSH) levels
rise after 4 and 12 h, respectively, and are elevated for
24–36 h. The amplitudes of the surge are similar to
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those observed during the normal menstrual cycle [7].
However, hCG-mediated LH activity persists for several
days into the luteal phase [8, 9].
Consequently, the two triggering agents affect oocyte
maturation in different ways. Does this difference affect oo-
cyte development and subsequent embryo quality? A recent
study showed that GnRHa triggering results in the retrieval
of more metaphase II (MII) oocytes compared with hCG
triggering [8]. This was related to the endogenous FSH
surge elicited along with the LH surge after GnRHa trigger-
ing [8, 9]. Recently, Munoz et al. explored the effect of con-
trolled ovarian stimulation and the ovulation triggering
factor (GnRHa + hCG triggering versus GnRH antagonist
+GnRHa triggering) on embryo development and kinetics
[10]. They reported that embryos from cycles involving
GnRH antagonist +GnRHa treatment cleaved faster than
embryos derived from patients co-treated with a GnRHa +
hCG. Their findings might be related to either the stimula-
tion protocol or the triggering agent. Insufficient data have
compared the steps following GnRHa- and hCG-triggered
cycles using the same stimulation protocol, including
fertilization and embryo developmental kinetics.
Therefore, this study compared the effects of hCG and
GnRHa triggering on embryo developmental kinetics in
antagonist cycles.
Methods
This retrospective cohort study analyzed the data on em-
bryos from 152 couples undergoing intracytoplasmic sperm
injection cycles from May 2014 to May 2015. The study
was conducted at the Novafertil IVF Center in Konya,
Turkey. The study protocol was approved by the Institu-
tional Review Board. Exclusion criteria were endometriosis,
poor ovarian reserve, azospermia, age > 36 years.
Ovarian stimulation
All patients followed a GnRH antagonist protocol. Ovarian
stimulation was initiated with recombinant FSH (Puregon;
MSD, Turkey or Gonal-F; Merck Serono, Turkey) on day 2
or 3 of the cycle and continued until the day of ovulation
trigger. Cycles were monitored using ultrasound scanning.
A GnRH antagonist, either ganirelix (Orgalutran; MSD,
Turkey) or cetrorelix (Cetrotide; Merck Serono, Turkey),
was administered when the leading follicle attained a max-
imum diameter of 14 mm. When at least two follicles had
reached diameters of 17 mm, final oocyte maturation was
triggered by administering 0.2 mg of the GnRHa triptorelin
(Gonapeptyl; Ferring, Turkey) in Group 1 or recombinant
hCG (Ovitrelle; Merck Serono, Turkey) in Group 2.
Oocyte retrieval and intracytoplasmic sperm injection
Transvaginal oocyte retrieval was performed 35 h after
triggering. Intracytoplasmic sperm injection was per-
formed in all patients. Embryos were evaluated on third
day, and up to two embryos were transferred per patient
on day 3 of development. All embryos were selected ac-
cording to their morphological evaluation and embryo
kinetics data were not used for embryo selection. For
luteal support, all patients in Group 1 were given 90 mg
progesteron gel (8 %) (Crinone gel, Merck Serono,
Turkey), 50 mg/day of intramuscular progesterone
(Progestan amp 50 mg, Koçak Farma, Turkey) and
4 mg/day estradiol hemihydrate (Estrofem 2 mg, Novo
Nordis; Turkey). All patients in Group 2 were given
90 mg progesteron gel (8 %) (Crinone gel, Merck
Serono, Turkey).
Time-lapse imaging
Images of each embryo were acquired every 20 min in
seven focal planes, initiated after insemination. The im-
ages were analyzed using Embryo Viewer software,
which annotates embryonic developmental events with
the corresponding time in hours after microinjection.
The times from insemination to the following events
were analyzed: when two pronuclei were visible (2PN);
when second polar body was detected (PB2), pronuclear
fading (PNF), when both pronuclei disappear; first cleav-
age, when the zygote divides into two cells (t2); and
when cleavage giving rise to 3 to 9 cells is observed for
the first time (t3 to t9, respectively). The intervals be-
tween two consecutive cleavages were also analyzed. The
duration of the second cell cycle (cc2 = t3 – t2) is the
time from the division into a two-blastomere embryo
until the time to the division into a three-blastomere
embryo, and second synchrony (s2 = t4 – t3) is the time
from this division into a four-blastomere embryo.
Morphokinetic categories
Recently, Meseguer et al. reported the optimal ranges of
the morphokinetic parameters t5, s2, and cc2 [11]. The
ranges of these parameters used in this current study were
as follows: t5 = 48.8–56.6 h, s2 < 0.76 h, and cc2 < 12 h.
Embryos within these ranges were described as optimal
embryos having the highest probability of implantation.
Statistical analysis
The Statistical Package for the Social Sciences 20 (SPSS,
Chicago, USA) was used for the statistical analysis. The
results were analyzed using Student’s t-test to compare
timings and the chi-square test to compare proportions.
A p-value of less than 0.05 was considered to be statisti-
cally significant.
Results
A total of 152 women were included in this study. The
groups did not differ in terms of age, body mass index
(BMI), day 3 FSH, total FSH dose, peak E2 levels, numbers
of oocytes, MII oocytes, embryos, embryos transferred,
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stimulation days, or implantation and pregnancy rates
(Table 1).
When the embryo developmental kinetics were evalu-
ated (Table 2), some early developmental events oc-
curred significantly later in embryos derived from cycles
triggered with hCG (n = 102 patients, n = 487 embryos)
than in embryos derived from cycles triggered with a
GnRHa (n = 50 patients, n = 252 embryos). The times
from insemination to tPB2, tPNF, t2, t3, t5, and t6 were
significantly shorter in the GnRHa triggered group
(Group 1). The groups did not differ significantly in
terms of t4, t7, t8, t9, cc2, and s2, but cc3 was significantly
shorter in Group 1 than in Group 2.
The percentage of optimal embryos based on the rele-
vant morphokinetic variables were compared according
to type of triggering agent. Variables analyzed were the
time of cleavage to five cells (t5), second cell cycle (cc2),
duration of the period as a two-cell blastomere embryo
(t3 – t2), and synchrony in division from two-cell blasto-
mere embryos to four-cell blastomere embryos (s2).
There were no significant difference between groups ac-
cording to t5. However percentage of optimal embryos
according to s2 and cc2 were significantly higher in
GnRH agonist group (Group1) than hCG triggering
group (p < 0.05) (Table 3)
Discussion
Embryo competence depends on oocyte quality, which is
affected by different factors, including the treatment mo-
dality [12, 13]. We do not know the exact effect of the
dosages and types of drugs on oocytes in IVF. Therefore,
it was suggested that mild stimulation protocols and nat-
ural cycles would reduce aneuploidy rates and increase
embryo quality [12]. However, every step during
ovulation induction could affect the oocytes and subse-
quent embryo development.
Triggering oocyte maturation is the last important step
of ovulation induction. For a long time, hCG has been
used as a triggering agent because of its homology with
LH and extended half-life. Although the extended half-
life of this molecule might be advantageous for luteal
support, its effect on oocyte maturation is not clear and
hCG-mediated LH activity differs from natural cycles.
Recently, GnRH agonists have been used as the trigger-
ing agent, especially in patients at a high risk of OHSS
in GnRH antagonist cycles. The GnRHa displaces the
GnRH antagonist from the GnRH receptor, inducing ini-
tial activation (flare-up) of LH and FSH, similar to that
of the natural cycle before receptor downregulation [14].
This seems to be a more physiological mode of oocyte
maturation. We examined whether there is a difference
in the development of these oocytes after GnRHa trig-
gering. Limited data are available on this subject in the
literature. To our knowledge, this is the first study to
evaluate embryo kinetics after the use of different
oocyte-triggering agents in patients undergoing the same
treatment protocol. Our results confirmed that the
oocyte-triggering agent affected the early developmental
kinetics of oocytes and embryos.
Interestingly, we found that the time intervals during
early embryo development were shorter in GnRHa-
triggered cycles. A recent report evaluated the effect of
different treatment protocols combined with different
triggering agents and found that embryos cleaved faster,
especially in the early developmental steps, following an
antagonist protocol plus GnRHa triggering compared
with a GnRHa protocol plus hCG triggering [10]. Our
results were similar. However, the stimulation protocols
Table 1 Demographic characteristics of the two study groups
GnRHa triggering (n = 50) hCG triggering (n = 102) p
Age 28.35 (4.03) 28.70 (2.33) NS
BMI 24.3 (4.08) 23.7 (3.82) NS
Day3 FSH 6.1 (2.8) 5.2 (2.1) NS
Total FSH dose 1895 (634) 2091 (642) NS
Peak E2 levels 3461 (1722) 3344 (1648) NS
No. oocytes 16.78 (5.27) 15.54 (6.45) NS
No. oocytes MII 11.03 (5.28) 10.74 (4.26) NS
No. embryos 7.16 (3.61) 7.27 (331) NS
No. embryos transferred 1.74 (0.25) 1.63 (0.25) NS
Stimulation days 9.74 (2.16) 10.30 (1.45) NS
Pregnancy rate (%) 64 (32/50) 63.7 (65/102) NS
Clinical pregnancy rate (%) 50 (25/50) 45 (46/102) NS
Implantation rate (%) 40 (35/86) 35 (58/165) NS
Results are presented as means (SD) when appropriate
NS no statistically significant differences were found, BMI body mass index, FSH follicle stimulating hormone, E2 Estradiol
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also differed in the aforementioned study groups. There-
fore, both stimulation and triggering factors affected the
results. In comparison, in our study, both groups
followed a GnRH antagonist protocol. Therefore, their
result might also be related to triggering factors, rather
than the stimulation protocol.
In this study, we found that oocytes were fertilized
earlier and that the PNF, t2, t3, t5, and t6 intervals were
shorter, while we did not detect any difference in the
later events. What is the role of early developmental kin-
etics in subsequent embryo development? Previous stud-
ies have compared early and late cleaving embryos and
found that significantly more early cleaving embryos
were good-quality embryos and the transfer of early
cleavage embryos resulted in higher implantation and
pregnancy rates [15–17]. Recently, Lemmen et al. re-
ported that the disappearance of pronuclei and first div-
ision occur earlier in embryos that implant and cell
number is higher on day 2 of embryonic development
[18]. Wong et al. found a correlation between reaching
the blastocyst stage and the first, second, and third cell
divisions [19]. Meseguer et al. evaluated the use of mor-
phokinetics as a predictor of embryo implantation and
reported six discriminative morphokinetic parameters
(t2, t3, t4, t5, cc2, and s2) that were correlated with im-
plantation [11]. In our study, the durations of t2, t3, and
t5 of GnRHa-triggered embryos were shorter than for
hCG-triggered embryos. Unfortunately, we could not
evaluate the relationship between these differences in
early developmental kinetics and pregnancy rates be-
cause we did not use embryo developmental kinetics for
embryo selection. However, the proportion of optimal
embryos based on the relevant morphokinetic variables
(s2 and cc2) which are considered to have a strong pre-
dictive potential of embryo competence were signifi-
cantly higher in GnRH agonist triggered group. Thus the
optimal time intervals stated above are related to higher
implantation potential [17–19].
What causes the difference in the early embryologic
developmental kinetics between GnRHa- and hCG-
triggered cycles? One explanation might be the oocyte
maturation process. Some recent studies focused on the
oocyte maturation rate after hCG and GnRHa triggering,
and found that the number of oocytes retrieved, percent-
age of mature oocytes, and number of top-quality em-
bryos were either comparable or in favor of the GnRHa
trigger [8, 20]. These findings were related to different
physiological events that happened after hCG and
GnRHa triggering. Therefore, the effects of these agents
differ in duration and receptor activation in some in-
stances [20–22]. The duration of the LH surge after
hCG triggering is longer than with GnRHa triggering,
Table 2 Embryo developmental kinetics according to the type of oocyte maturation triggering agent
GnRHa triggering (Group 1 n:252) hCG triggering (Group 2 n:487) P
tPB2 4.5 (1.7) 5.4 (1.8) 0.000
tPNf 24.8 (5.2) 26.7 (5.2) 0.000
t2 (h) 32.2 (6.2) 34.3 (5.5) 0.009
t3 (h) 38.5 (6.0) 39.9 (5.1) 0.027
t4 (h) 40.6 (6.3) 41.7 (5.3) 0.101
t5 (h) 47.0 (7.9) 50.8 (7.1) 0.000
t6 (h) 52.1 (7.3) 54.6 (6.2) 0.002
t7 (h) 57.5 (8.2) 57.8 (5.2) 0.871
t8 (h) 63.2 (6.3) 62.5 (5.1) 0.589
t9+ (h) 64.5 (5.9) 64.9 (4.8) 0.996
cc2 (h) 6.9 (5.9) 6.3 (4.1) 0.321
s2 (h) 2.6 (4.2) 2.0 (2.2) 0.151
cc3 (h) 9.7 (6.1) 11.5 (4.5) 0.006
t4 – t2 (h) 9.5 (6.4) 8.6 (4.6) 0.071
t8 – t4 (h) 24.3 (6.3) 23.5 (5.1) 0.251
Results are presented as means(SD) when appropriate
t time, h hour, tPB2 appearance of second polar body tPNf both pronuclei faded, cc cell cycle s, synchrony
Table 3 Percentages of optimal embryos whose cleavages are
included in optimal timing ranges with a predicted higher
implantation potential (Meseguer et al. 2011) according to type
of triggering
Embryo category GnRHa triggering hCG triggering p
T5 (%) 15.4 17.4 NS
S2 (%) 42.0 24.8 0.000
CC2 (%) 52.3 43.1 0.005
Data are presented as % (n) for each category. The proportions of optimal
embryos in each category were compared using the χ2 test. NS. no statistically
significant differences were found
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i.e., days versus 24 h, respectively [18]. LH has a greater
impact on AKT and extracellular signal regulated kinase
(ERK1/2) phosphorylation and is responsible for granu-
losa cells proliferation, differentiation, and survival, while
hCG generates more intracellular cAMP accumulation,
which stimulates steroidogenesis [22]. HCG induces ele-
vated follicular fluid progesterone levels, suggesting that
there are differences in the oocyte microenvironment
just before ovulation compared with the endogenous LH
surge [23]. Recent studies also suggested a potential fa-
vorable impact of FSH in the process of nuclear matur-
ation by actively promoting the resumption of meiosis
[19, 24, 25]. Erb et al. reported a significantly greater
yield of high-quality embryos in the GnRHa-triggered
group in donor cycles [26]. They suggested that the lon-
ger half-life of hCG causes over-luteinization of the re-
cruited follicles, affecting oocyte and embryo quality.
Although GnRHa triggering seems to favor oocyte
maturation and embryo development, one major disad-
vantage of GnRHa-triggered cycles is the luteolytic effect
after GnRHa triggering, which may necessitate adding
low-dose hCG for luteal support in fresh IVF cycles [8].
A dual or double trigger using both GnRHa and hCG
might improve oocyte and embryo quality, while sup-
porting the luteal phase. Lin et al. found that signifi-
cantly more oocytes were retrieved, with more mature
oocytes, and more embryos cryopreserved, with a signifi-
cant increase in implantation, clinical pregnancy, and
live birth rates, as compared with the hCG-triggered
group [27]. Decleer et al. reported a greater number of
excellent oocytes and cryopreserved embryos after dual
triggering, compared with hCG only [28]. A recent paper
recommended prolonging the time interval between
ovulation triggering with a GnRHa and oocyte pick-up
to overcome any existing impairment in granulosa cell
function, oocyte meiotic maturation, or cumulus expan-
sion for patients with abnormal follicular maturation
[29]. We did not evaluate the effects of a dual trigger on
oocyte development. Future studies evaluating the em-
bryo developmental kinetics after a dual trigger will give
more information on the subject.
Our findings suggested favorable embryo develop-
mental kinetics after GnRHa triggering. This may be re-
lated to the more physiological maturation process in
response to GnRHa as previously reported by others
[24–26]. Therefore, another patient-friendly option
might be GnRHa triggering combined with transfer of
these embryos in a natural thaw cycle with a natural
endometrium, especially for patients at high risk of
OHSS. Elective vitrification is an alternative embryo
transfer strategy to achieve better perinatal outcomes
following assisted reproduction technology treatment
[30]. Future randomized controlled studies will provide
more information.
Conclusions
In conclusion, the method used to trigger oocyte matur-
ation seems to affect the dynamic parameters of early
oocyte and embryo development. Larger randomized
controlled studies are needed to evaluate the clinical ef-
fects of these findings.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
ASG conception of study, acquisition of data, revising the manuscript for
intellectual content, approval of the final version. FG conception of the
study, data analysis and interpretation, drafting the manuscript, approval of
final version. MSU revising the manuscript for intellectual content, BI
approval of the final version acquisition of data, approval of the final version
MK revising the manuscript for intellectual content, approval of the final
version. NO acquisition of data, approval of the final version, EEO revising the
manuscript for intellectual content, approval of the final version. AA
acquisition of data, approval of the final version. All authors read and
approved the final manuscript.
Acknowledgement
We thank all patients and staff of the study centre (Ahmet Şalvarcı, Fuat Ali,
Dilek Incesu).
The English in this document has been checked by at least two professional
editors, both native speakers of English. For a certificate, please see: http://
www.textcheck.com/certificate/e3pxvx.
Funding
No funding was saught for this report.
Author details
1Novafertil IVF Centre, Yeni Meram yolu No:75, Meram, Konya, Turkey.
2Department of Obstetrics and Gynecology, Izmir University Hospital, Izmir,
Turkey. 3Department of Obstetrics and Gynecology, Baskent University
Hospital, Konya, Turkey. 4Department of Obstetrics and Gynecology,
Necmettin Erbakan University, Konya, Turkey.
Received: 4 December 2015 Accepted: 18 March 2016
References
1. Baxter Bendus AE, Mayer JF, Shipley SK, Catherino WH. Interobserver and
intraobserver variation in day 3 embryo grading. Fertil Steril. 2006;86:1608–15.
2. Montag M, Toth B, Strowitzki T. New approaches to embryo selection.
Reprod Biomed Online. 2013;27(5):539–46.
3. Armstrong S, Arroll N, Cree LM, Jordan V, Farquhar C. Time-lapse systems for
embryo incubation and assessment in assisted reproduction. Cochrane
Database Syst Rev. 2015;27(2):CD011320.
4. Steptoe PC, Edwards RG. Birth after reimplantation of a human embryo.
Lancet. 1978;2(8085):366.
5. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J,
Abou-Setta AM. Gonadotropin-releasing hormone antagonists for assisted
reproductive technology. Cochrane Database Syst Rev. 2011;11(5):CD001750.
6. Kol S, Humaidan P, Itskovitz-Eldor J. GnRH agonist ovulation trigger and
hCG-based, progesterone-free luteal support: a proof of concept study.
Hum Reprod. 2011;26:2874–7.
7. Youssef MAF, Abdelmoty HI, Ahmed MAS, Elmohamady M. GnRH agonist for
final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment
cycles: Systematic review and meta-analysis. J Adv Res. 2015;6:341–9.
8. Humaiden P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P,
Fatemi HM. The luteal phase after GnRH-agonist triggering of ovulation:
present and future perspectives. Reprod Biomed Online. 2012;24:134–41.
9. Kol S, Humaiden P. LH (as HCG) and FSH surges for final oocyte maturation:
sometimes it takes two to tango? Reprod Biomed Online. 2010;21:590–2.
10. Munoz M, Cruz M, Humaidan P, Garrido N, Perez-Cano I, Meseguer M. The
type of GnRH analogue used during controlled ovarian stimulation
influences early embryo developmental kinetics: a time lapse study. Eur J
Obstet Gynecol Reprod Biol. 2013;168:167–72.
Gurbuz et al. Journal of Ovarian Research  (2016) 9:22 Page 5 of 6
11. Meseguer M, Herrero J, Tejera A, Hilligsoe KM, Ramsing NB, Remohi J. The
use of morphokinetics as a predictor of embryo implantation. Hum Reprod.
2011;26:2658–71.
12. Rubio C, Mercader A, Alama P, Lizan C, Rodrigo L, Labarta E, Melo M, Pellicer A,
Remohi J. Prospective cohort study in high responder oocyte donors using
two hormonal stimulation protocols: impact on embryo aneuploidy and
development. Hum Reproduc. 2010;25:2290–7.
13. Baart EB, Macklon NS, Fauser BJ. Ovarian stimulation and embryo quality.
Reproduct Biomed Online. 2009;18 Suppl 2:45–50.
14. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO,
Papanikolaou EG, Andersen CY. GnRHa trigger and individualized luteal
phase hCG support according to ovarian response to stimulation: two
prospective randomized controlled multi-centre studies in IVF patients. Hum
Reprod. 2013;28(9):2511–21.
15. Orvieto R. Triggering final follicular maturation-hCG, GnRH-agonist or both,
when and to whom? J Ovarian Res. 2015;8:60.
16. Lundin K, Bergh C, Hardarson T. Early embryo cleavage is a strong indicator
of embryo quality in human IVF. Hum Reprod. 2001;16:2652–7.
17. Fenwick J, Platteau P, Murdoch AP, Herbert M. Time from insemination to
first cleavage predicts developmental competence of human
preimplantation embryosin vitro. Hum Reprod. 2002;17:407–12.
18. Lemmen JG, Agerholm I, Ziebe S. Kinetic markers of human embryo quality
using time-lapse recordings of IVF/ICSI fertilized oocytes. Reprod Biomed
Online. 2008;17:385–91.
19. Wong CC, Loewke KE, Bossert NL, Behr B, De Jonge CJ, Baer TM, Reijo Pera RA.
Non invasive imaging of human embryos before embryonic genome activation
predicts development to the blastocyst stage. Nat Biotechnol. 2010;28:1115–21.
20. Van Montfoort AP, Dumuolin JC, Kester AD, Evers JL. Early cleavage is a
valuable addition to existing embryo selection parameters: a study using
single embryo transfers. Hum Reprod. 2004;19:2103–8.
21. Fauser BC, De Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz Eldor J, et al.
Endocrine profiles after triggering of final oocyte maturation with GnRH
agonist after cotreatment with the GnRH antagonist ganirelix during
ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab.
2002;87:709–15.
22. Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliassacchi D, et al.
LH and HCG action on the same receptor results in quantitatively and
qualitatively different intracellular signaling. PLoS One. 2012;7:e46682.
23. Yding Andersen C, Westergaard LG, Figenschau Y, Bertheussen K, Forsdahl
F. Endocrine composition of follicular fluid comparing human chorionic
gonadotrophin to a gonadotrophin-releasing hormone agonist for
ovulation induction. Hum Reprod. 1993;8:840–3.
24. Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL. Follicle
stimulating hormone alone supports follicle growth and oocyte
development in gonadotrophin-releasing hormone antagonist-treated
monkey. Hum Reprod. 1995;10:1658–66.
25. Yding Andersen C, Leonardsen L, Ulloa-Aguirre A, Barrios-De Tomasi J,
Moore L, Byskov AG. FSH-induced resumption of meiosis in mouse oocytes:
effect of different isoforms. Mol Hum Reprod. 1999;5:726–31.
26. Erb TM, Vitek W, Wakim ANG. Gonadotropin realesing hormone agonist or
human chorionic gonadotropin for final oocyte maturation in an oocyte
donor program. Fertil Steril. 2010;93:374–8.
27. Lin MH, Wu FS, Lee RK, Li SH, Lin SY, Hwu YM. Dual trigger with
combination of gonadotropin-releasing hormone agonist and human
chorionic gonadotropin significantly improves the live-birth rate for normal
responders in GnRH antagonist cycles. Fertil Steril. 2013;100(5):1296–302.
28. Decleer W, Osmanagaoglu K, Seynhave B, Kolibianakis S, Tarlatzis B, Devroey P.
Comparison of hCG triggering versus hCG in combination with a GnRH
agonist: a prospective randomized controlled trial. Facts Views Vis Obygyn.
2014;6(4):203–9.
29. Uygur D, Alkan RN, Batuoglu S. Recurrent empty follicle syndrome. J Assist
Reprod Genet. 2003;20:390–2.
30. Li Z, Wang Y, Ledger W, Edgar DH, Sullivan EA. Clinical outcomes following
cryopreservation of blastocysts by vitrification or slow freezing: a
population-based cohort study. Hum Reprod. 2014;29(12):2794–801.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gurbuz et al. Journal of Ovarian Research  (2016) 9:22 Page 6 of 6
